Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today    symbols : Snynf    save search
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
SNY | News | $47.125 1.78% 1.75% 2.1M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
study
Gainers vs Losers
74% 26%

Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M twitter stocktwits trandingview |

AGBA | $2.5 100.0% 56.6% 200M twitter stocktwits trandingview |
Finance
MLEC | $2.47 76.43% 42.62% 78M twitter stocktwits trandingview |
n/a
EDBL | News | $6.26 66.49% 40.13% 16M twitter stocktwits trandingview |

ATGL | $2.86 46.25% 32.8% 180K twitter stocktwits trandingview |

ZAPP | $0.2175 47.16% 32.05% 16M twitter stocktwits trandingview |
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M twitter stocktwits trandingview |
n/a
VIVK | $1.48 38.32% 27.7% 530K twitter stocktwits trandingview |
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M twitter stocktwits trandingview |

SDIG A | $3.635 35.13% 26.0% 1M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.